Insights › Medicine & pharma › November 16, 2026
Medicine & pharma · Pipeline & development

Novo presents preclinical and human data suggesting a role for amylin and calcitonin receptor activation in preserving bone during weight loss at ObesityWeek®

PR Newswire (Health) Published: Results

Novo's investigational CagriSema and cagrilintide reduced bone loss in a preclinical model of menopause¹ In small studies conducted in humans, the dual amylin and calcitonin receptor agonists, cagrilintide and zenagamtide, but not the selective amylin receptor agonist NN1213, were...

Original source
Read the source — prnewswire.com ↗

We link to the original publisher. The summary above is a short guide; read the original for the full details.

More in Medicine & pharma

See everything in Medicine & pharma →

Look into this further

Read every record in your own language

This page shows the three newest items per field. Members see every record in the field, in 109 languages, with the search engines that work on them.

Read it all — start from $3No app-store installation. Cancel any time.